News | July 05, 2023
Venus Remedies gets marketing approvals for oncology medicine from 4 key markets
With this, the number of marketing approvals for its oncology products across 75 countries has gone up to 503
With this, the number of marketing approvals for its oncology products across 75 countries has gone up to 503
This trial is a multi-national, phase 2/3, open-label, randomized, controlled clinical study of utidelone injectable
UTD2 is the world's first oral epothilone microtubule inhibitor
Tremelimumab in combination with Durvalumab is indicated for the treatment of patients with unresectable hepatocellular carcinoma (uHCC)
The company moves a step closer towards achieving its goal of emerging as the top oncology medicine supplier from India in the ASEAN region
Company intends to increase sales in the UK to approximately 2 million Euros by focusing on seven molecules which are already registered in the country
China is among the top countries reporting a high number of diagnosed prevalent cases for gastric, breast, and bladder cancers among the 16 major markets
First release of Rs.166 crores incentives under PLI scheme for pharmaceuticals
Palbociclib has a unique mechanism of action which helps in delaying disease progression when co-administered with hormonal therapies
Acquisition expands Merck’s growing hematology portfolio
Subscribe To Our Newsletter & Stay Updated
